Lisata Therapeutics, Inc. SEC filings LSTA
Lisata Therapeutics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to May 17, 2011. Its latest annual report, Form ARS, was filed on Oct 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Oct 2, 2026 | — |
| SC TO-T/A | Filing | Jul 28, 2026 | — |
| SC 14D9/A | Filing | Jul 21, 2026 | — |
| SC 14D9/A | Filing | Jul 17, 2026 | — |
| SC TO-T/A | Filing | Jul 17, 2026 | — |
| SC 14D9/A | Filing | Jul 13, 2026 | — |
| SC TO-T/A | Schedule to-t/a | Jul 10, 2026 | — |
| SC 14D9/A | Filing | Jul 2, 2026 | — |
| SC 14D9 | Filing | Jun 10, 2026 | — |
| SC TO-T | Filing | Jun 10, 2026 | — |
| SC14D9C | Filing | Jun 9, 2026 | — |
| SC TO-C | Filing | Jun 1, 2026 | — |
| SC14D9C | Filing | Jun 1, 2026 | — |
| SC TO-C | Filing | May 29, 2026 | — |
| SC14D9C | Filing | May 29, 2026 | — |
| SC TO-C | Filing | May 4, 2026 | — |
| SC14D9C | Filing | May 4, 2026 | — |
| SC14D9C | Filing | Apr 15, 2026 | — |
| SC14D9C | Filing | Apr 3, 2026 | — |
| SC14D9C | Filing | Mar 9, 2026 | — |
| SC14D9C | Filing | Feb 27, 2026 | — |
| SC14D9C | Sc 14d9c | Jan 21, 2026 | — |
| EFFECT | Filing | May 9, 2024 | — |
| CORRESP | Letter to the SEC | May 7, 2024 | — |
| UPLOAD | Letter from the SEC | May 6, 2024 | — |
| 425 | Filing | Sep 2, 2022 | — |
| 425 | Filing | Aug 15, 2022 | — |
| 425 | Filing | Aug 10, 2022 | — |
| EFFECT | Filing | Jul 28, 2022 | — |
| CORRESP | Letter to the SEC | Jul 26, 2022 | — |
| 425 | Filing | Jul 6, 2022 | — |
| 425 | Filing | Jun 9, 2022 | — |
| 425 | Filing | Apr 27, 2022 | — |
| EFFECT | Filing | May 4, 2021 | — |
| CORRESP | Letter to the SEC | Apr 30, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2021 | — |
| EFFECT | Filing | Feb 5, 2021 | — |
| CORRESP | Letter to the SEC | Feb 3, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2021 | — |
| D | Filing | Feb 1, 2021 | — |
| EFFECT | Filing | Aug 27, 2020 | — |
| CORRESP | Letter to the SEC | Aug 25, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 25, 2020 | — |
| D | Filing | Jul 27, 2020 | — |
| EFFECT | Filing | Jun 29, 2020 | — |
| CORRESP | Letter to the SEC | Jun 25, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2020 | — |
| D | Filing | Jun 5, 2020 | — |
| D | Filing | May 12, 2020 | — |
| EFFECT | Filing | Aug 2, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2018 | — |
| CORRESP | Letter to the SEC | Jul 31, 2018 | — |
| EFFECT | Filing | Sep 19, 2017 | — |
| CORRESP | Letter to the SEC | Sep 15, 2017 | — |
| EFFECT | Filing | Dec 19, 2016 | — |
| CORRESP | Letter to the SEC | Dec 16, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2016 | — |
| D | Filing | Sep 26, 2016 | — |
| EFFECT | Filing | Jun 6, 2016 | — |
| CORRESP | Letter to the SEC | Jun 3, 2016 | — |
| CT ORDER | Filing | May 16, 2016 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2016 | — |
| D | Filing | Mar 18, 2016 | — |
| EFFECT | Filing | Aug 28, 2015 | — |
| CORRESP | Letter to the SEC | Aug 27, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2015 | — |
| EFFECT | Filing | Jun 26, 2014 | — |
| D | Filing | May 8, 2014 | — |
| CERTNAS | Auto-generated paper document | Aug 5, 2013 | — |
| 25 | Filing | Aug 2, 2013 | — |
| 8-A12B | Filing | Aug 2, 2013 | — |
| EFFECT | Filing | May 23, 2013 | — |
| EFFECT | Filing | Dec 28, 2012 | — |
| EFFECT | Filing | Oct 3, 2012 | — |
| EFFECT | Filing | Oct 3, 2012 | — |
| EFFECT | Filing | Oct 3, 2012 | — |
| CORRESP | Letter to the SEC | Sep 28, 2012 | — |
| CORRESP | Letter to the SEC | Sep 28, 2012 | — |
| AW | Filing | Sep 25, 2012 | — |
| RW WD | Filing | Sep 25, 2012 | — |
| CORRESP | Letter to the SEC | Sep 18, 2012 | — |
| RW | Filing | Sep 17, 2012 | — |
| UPLOAD | Letter from the SEC | Sep 14, 2012 | — |
| 25-NSE | Delisting notice | Jul 16, 2012 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2012 | — |
| CORRESP | Letter to the SEC | Jul 5, 2012 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2012 | — |
| CORRESP | Letter to the SEC | Jun 15, 2012 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2012 | — |
| EFFECT | Filing | Sep 30, 2011 | — |
| EFFECT | Filing | Sep 15, 2011 | — |
| 425 | Form 8-k | Aug 24, 2011 | — |
| 425 | Current report | Aug 18, 2011 | — |
| 425 | Current report | Jul 22, 2011 | — |
| 425 | Filing | Jul 20, 2011 | — |
| 425 | Current report | Jul 14, 2011 | — |
| EFFECT | Filing | Jun 13, 2011 | — |
| CORRESP | Letter to the SEC | Jun 9, 2011 | — |
| CORRESP | Letter to the SEC | May 27, 2011 | — |
| UPLOAD | Letter from the SEC | May 26, 2011 | — |
| NT 10-Q | Filing | May 17, 2011 | Mar 31, 2011 |
Showing 101 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LSTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Basking Ridge, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 320017
- Former names
- Caladrius Biosciences, Inc. (until Sep 15, 2022); CALADRIUS BIOSCIENCES, INC. (until Sep 15, 2022); NeoStem, Inc. (until Jun 5, 2015); PHASE III MEDICAL INC/DE (until Sep 1, 2006); CORNICHE GROUP INC /DE (until Aug 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.